{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:09:21Z","timestamp":1769695761830,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40744-023-00609-2","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T12:01:41Z","timestamp":1698753701000},"page":"1753-1768","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-9290","authenticated-orcid":false,"given":"Anisha B.","family":"Dua","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerri","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3785-2448","authenticated-orcid":false,"given":"Stefano","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8338-027X","authenticated-orcid":false,"given":"Dimitrios A.","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jud C.","family":"Janak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Blachley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Roberts-Toler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7097-188X","authenticated-orcid":false,"given":"Kelechi","family":"Emeanuru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6674-9901","authenticated-orcid":false,"given":"Joel M.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1045-1310","authenticated-orcid":false,"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"key":"609_CR1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320:1360\u201372. https:\/\/doi.org\/10.1001\/jama.2018.13103.","journal-title":"JAMA"},{"key":"609_CR2","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.3390\/cells10112857","volume":"10","author":"AF Radu","year":"2021","unstructured":"Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021;10:2857. https:\/\/doi.org\/10.3390\/cells10112857.","journal-title":"Cells"},{"key":"609_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3\u201318.","journal-title":"Ann Rheum Dis"},{"key":"609_CR4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73:924\u201339. https:\/\/doi.org\/10.1002\/acr.24596.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"609_CR5","doi-asserted-by":"publisher","first-page":"686155","DOI":"10.3389\/fimmu.2021.686155","volume":"12","author":"J Huang","year":"2021","unstructured":"Huang J, Fu X, Chen X, et al. Promising therapeutic targets for treatment of rheumatoid arthritis. Front Immunol. 2021;12:686155. https:\/\/doi.org\/10.3389\/fimmu.2021.686155.","journal-title":"Front Immunol"},{"key":"609_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/bor.0000000000000491","volume":"30","author":"M Bonelli","year":"2018","unstructured":"Bonelli M, Scheinecker C. How does abatacept really work in rheumatoid arthritis? Curr Opin Rheumatol. 2018;30:295\u2013300. https:\/\/doi.org\/10.1097\/bor.0000000000000491.","journal-title":"Curr Opin Rheumatol"},{"key":"609_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/jir.s219586","volume":"13","author":"R Harrington","year":"2020","unstructured":"Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res. 2020;13:519\u201331. https:\/\/doi.org\/10.2147\/jir.s219586.","journal-title":"J Inflamm Res"},{"key":"609_CR8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/25785826.2020.1770948","volume":"43","author":"A Morinobu","year":"2020","unstructured":"Morinobu A. JAK inhibitors for the treatment of rheumatoid arthritis. Immunol Med. 2020;43:148\u201355. https:\/\/doi.org\/10.1080\/25785826.2020.1770948.","journal-title":"Immunol Med"},{"key":"609_CR9","doi-asserted-by":"publisher","first-page":"1759720X2110026","DOI":"10.1177\/1759720x211002682","volume":"13","author":"A Migliore","year":"2021","unstructured":"Migliore A, Pompilio G, Integlia D, et al. Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211002682. https:\/\/doi.org\/10.1177\/1759720x211002682.","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"609_CR10","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/s0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391:2513\u201324. https:\/\/doi.org\/10.1016\/s0140-6736(18)31116-4.","journal-title":"Lancet"},{"key":"609_CR11","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","volume":"78","author":"RM Fleischmann","year":"2019","unstructured":"Fleischmann RM, Genovese MC, Enejosa JV, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78:1454\u201362. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215764.","journal-title":"Ann Rheum Dis"},{"key":"609_CR12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1136\/annrheumdis-2020-218412","volume":"80","author":"RM Fleischmann","year":"2021","unstructured":"Fleischmann RM, Blanco R, Hall S, et al. Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis. Ann Rheum Dis. 2021;80:432\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218412.","journal-title":"Ann Rheum Dis"},{"key":"609_CR13","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/cells9040880","volume":"9","author":"YJ Lin","year":"2020","unstructured":"Lin YJ, Anzaghe M, Schulke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9:880. https:\/\/doi.org\/10.3390\/cells9040880.","journal-title":"Cells"},{"key":"609_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrd.2018.45","volume":"17","author":"C Garbers","year":"2018","unstructured":"Garbers C, Heink S, Korn T, et al. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018;17:395\u2013412. https:\/\/doi.org\/10.1038\/nrd.2018.45.","journal-title":"Nat Rev Drug Discov"},{"key":"609_CR15","unstructured":"CorEvitas. Rheumatoid arthritis registry. https:\/\/www.corevitas.com\/registry\/rheumatoid-arthritis. Accessed 23 Mar 2022."},{"issue":"1","key":"609_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.autrev.2005.07.006","volume":"5","author":"JM Kremer","year":"2006","unstructured":"Kremer JM. The CORRONA database. Autoimmun Rev. 2006;5(1):46\u201354. https:\/\/doi.org\/10.1016\/j.autrev.2005.07.006.","journal-title":"Autoimmun Rev"},{"key":"609_CR17","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1002\/acr.20621","volume":"63","author":"JK Anderson","year":"2011","unstructured":"Anderson JK, Zimmerman L, Caplan L, et al. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res (Hoboken). 2011;63:S14-36. https:\/\/doi.org\/10.1002\/acr.20621.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"609_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1136\/ard.60.4.344","volume":"60","author":"MC Greenwood","year":"2001","unstructured":"Greenwood MC, Doyle DV, Ensor M. Does the Stanford Health Assessment Questionnaire have potential as a monitoring tool for subjects with rheumatoid arthritis? Ann Rheum Dis. 2001;60:344\u20138. https:\/\/doi.org\/10.1136\/ard.60.4.344.","journal-title":"Ann Rheum Dis"},{"key":"609_CR19","doi-asserted-by":"publisher","first-page":"S240","DOI":"10.1002\/acr.20543","volume":"63","author":"GA Hawker","year":"2011","unstructured":"Hawker GA, Mian S, Kendzerska T, et al. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011;63:S240\u201352. https:\/\/doi.org\/10.1002\/acr.20543.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"609_CR20","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1002\/acr.21747","volume":"64","author":"F Tubach","year":"2012","unstructured":"Tubach F, Ravaud P, Martin-Mola E, et al. Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: results from a prospective multinational study. Arthritis Care Res (Hoboken). 2012;64:1699\u2013707. https:\/\/doi.org\/10.1002\/acr.21747.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"609_CR21","unstructured":"Kitchen H, Hansen BB, Abetz L, et al. Patient-reported outcome measures for rheumatoid arthritis: minimal important differences review [abstract]. In: 2013 ACR\/ARHP annual meeting. https:\/\/acrabstracts.org\/abstract\/patient-reported-outcome-measures-for-rheumatoid-arthritis-minimal-important-differences-review\/. Accessed 6 Apr 2022."},{"issue":"Suppl 11","key":"609_CR22","doi-asserted-by":"publisher","first-page":"S263","DOI":"10.1002\/acr.20579","volume":"63","author":"S Hewlett","year":"2011","unstructured":"Hewlett S, Dures E, Almeida C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S263\u201386. https:\/\/doi.org\/10.1002\/acr.20579.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"609_CR23","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.3899\/jrheum.080375","volume":"35","author":"D Khanna","year":"2008","unstructured":"Khanna D, Pope JE, Khanna PP, et al. The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice. J Rheumatol. 2008;35:2339\u201343. https:\/\/doi.org\/10.3899\/jrheum.080375.","journal-title":"J Rheumatol"},{"key":"609_CR24","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/rheumatology\/keaa259","volume":"60","author":"A Rubbert-Roth","year":"2021","unstructured":"Rubbert-Roth A, Aletaha D, Devenport J, et al. Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis. Rheumatology (Oxford). 2021;60:682\u201391. https:\/\/doi.org\/10.1093\/rheumatology\/keaa259.","journal-title":"Rheumatology (Oxford)"},{"key":"609_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/art.24282","volume":"61","author":"D Aletaha","year":"2009","unstructured":"Aletaha D, Funovits J, Ward MM, et al. Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline. Arthritis Rheum. 2009;61:313\u201320. https:\/\/doi.org\/10.1002\/art.24282.","journal-title":"Arthritis Rheum"},{"key":"609_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13075-018-1614-z","volume":"20","author":"V Strand","year":"2018","unstructured":"Strand V, Gossec L, Proudfoot CWJ, et al. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. Arthritis Res Ther. 2018;20:129. https:\/\/doi.org\/10.1186\/s13075-018-1614-z.","journal-title":"Arthritis Res Ther"},{"key":"609_CR27","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13075-016-1096-9","volume":"18","author":"V Strand","year":"2016","unstructured":"Strand V, Kosinski M, Chen CI, et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther. 2016;18:198. https:\/\/doi.org\/10.1186\/s13075-016-1096-9.","journal-title":"Arthritis Res Ther"},{"key":"609_CR28","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3390\/ijms23031246","volume":"23","author":"L Toth","year":"2022","unstructured":"Toth L, Juhasz MF, Szabo L, et al. Janus kinase inhibitors improve disease activity and patient-reported outcomes in rheumatoid arthritis: a systematic review and meta-analysis of 24,135 patients. Int J Mol Sci. 2022;23:1246. https:\/\/doi.org\/10.3390\/ijms23031246.","journal-title":"Int J Mol Sci"},{"key":"609_CR29","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/1756-185x.12822","volume":"19","author":"YH Lee","year":"2016","unstructured":"Lee YH, Bae SC. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis. 2016;19:1103\u201311. https:\/\/doi.org\/10.1111\/1756-185x.12822.","journal-title":"Int J Rheum Dis"},{"key":"609_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000798","volume":"5","author":"E Choy","year":"2019","unstructured":"Choy E, Freemantle N, Proudfoot C, et al. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor alpha inhibitors: systematic literature review and network meta-analyses. RMD Open. 2019;5: e000798. https:\/\/doi.org\/10.1136\/rmdopen-2018-000798.","journal-title":"RMD Open"},{"key":"609_CR31","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1136\/annrheumdis-2018-214918","volume":"78","author":"D Aletaha","year":"2019","unstructured":"Aletaha D, Maa JF, Chen S, et al. Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78:1609\u201315. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214918.","journal-title":"Ann Rheum Dis"},{"key":"609_CR32","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/rheumatology\/kex394","volume":"57","author":"G Kilcher","year":"2018","unstructured":"Kilcher G, Hummel N, Didden EM, et al. Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries. Rheumatology (Oxford). 2018;57:354\u201369. https:\/\/doi.org\/10.1093\/rheumatology\/kex394.","journal-title":"Rheumatology (Oxford)"},{"key":"609_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/s0140-6736(04)17670-8","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell PM. External validity of randomised controlled trials: \u201cTo whom do the results of this trial apply?\u201d Lancet. 2005;365:82\u201393. https:\/\/doi.org\/10.1016\/s0140-6736(04)17670-8.","journal-title":"Lancet"},{"key":"609_CR34","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/jcpt.13380","volume":"46","author":"YK Sung","year":"2021","unstructured":"Sung YK, Lee YH. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2021;46:984\u201392. https:\/\/doi.org\/10.1111\/jcpt.13380.","journal-title":"J Clin Pharm Ther"},{"key":"609_CR35","doi-asserted-by":"publisher","first-page":"1759720X2199956","DOI":"10.1177\/1759720X21999564","volume":"13","author":"C Weng","year":"2021","unstructured":"Weng C, Xue L, Wang Q, et al. Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720X21999564. https:\/\/doi.org\/10.1177\/1759720X21999564.","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"609_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001601","volume":"7","author":"S Mori","year":"2021","unstructured":"Mori S, Urata Y, Yoshitama T, et al. Tofacitinib versus tocilizumab in the treatment of biological-naive or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis. RMD Open. 2021;7: e001601. https:\/\/doi.org\/10.1136\/rmdopen-2021-001601.","journal-title":"RMD Open"},{"key":"609_CR37","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2013-203993","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Gottenberg JE, Rubbert-Roth A, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 2015;74:979\u201384. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203993.","journal-title":"Ann Rheum Dis"},{"key":"609_CR38","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13075-015-0776-1","volume":"17","author":"LR Harrold","year":"2015","unstructured":"Harrold LR, Reed GW, Magner R, et al. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry. Arthritis Res Ther. 2015;17:256. https:\/\/doi.org\/10.1186\/s13075-015-0776-1.","journal-title":"Arthritis Res Ther"},{"key":"609_CR39","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1136\/annrheumdis-2018-214529","volume":"78","author":"Y Tanaka","year":"2019","unstructured":"Tanaka Y, Fautrel B, Keystone EC, et al. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and\/or study design: phase III data in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78:890\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214529.","journal-title":"Ann Rheum Dis"},{"key":"609_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/acr2.11337","volume":"4","author":"JR Curtis","year":"2022","unstructured":"Curtis JR, Kremer JM, Reed G, et al. TNFi cycling versus changing mechanism of action in TNFi-experienced patients: Result of the Corrona CERTAIN comparative effectiveness study. ACR Open Rheumatol. 2022;4:65\u201373. https:\/\/doi.org\/10.1002\/acr2.11337.","journal-title":"ACR Open Rheumatol"},{"key":"609_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115327","volume":"28","author":"S Kaur","year":"2020","unstructured":"Kaur S, Bansal Y, Kumar R, et al. A panoramic review of IL-6: structure, pathophysiological roles and inhibitors. Bioorg Med Chem. 2020;28: 115327. https:\/\/doi.org\/10.1016\/j.bmc.2020.115327.","journal-title":"Bioorg Med Chem"},{"key":"609_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106985","volume":"88","author":"H Wang","year":"2020","unstructured":"Wang H, Wang Z, Wang L, et al. IL-6 promotes collagen-induced arthritis by activating the NLRP3 inflammasome through the cathepsin B\/S100A9-mediated pathway. Int Immunopharmacol. 2020;88: 106985. https:\/\/doi.org\/10.1016\/j.intimp.2020.106985.","journal-title":"Int Immunopharmacol"},{"key":"609_CR43","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/biom10071002","volume":"10","author":"J Angelini","year":"2020","unstructured":"Angelini J, Talotta R, Roncato R, et al. JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future. Biomolecules. 2020;10:1002. https:\/\/doi.org\/10.3390\/biom10071002.","journal-title":"Biomolecules"},{"key":"609_CR44","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.7150\/thno.47860","volume":"11","author":"X Yang","year":"2021","unstructured":"Yang X, Zhan N, Jin Y, et al. Tofacitinib restores the balance of gammadeltaTreg\/gammadeltaT17 cells in rheumatoid arthritis by inhibiting the NLRP3 inflammasome. Theranostics. 2021;11:1446\u201357. https:\/\/doi.org\/10.7150\/thno.47860.","journal-title":"Theranostics"},{"key":"609_CR45","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, et al. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35:1763\u201374. https:\/\/doi.org\/10.1007\/s12325-018-0805-y.","journal-title":"Adv Ther"},{"key":"609_CR46","doi-asserted-by":"crossref","unstructured":"Dua A, Ford K, Fiore S, et al. POS0606: disease activity and patients-reported outcomes after switching between IL-6 receptor inhibitors and JAK inhibitors: an analysis from the Corrona Registry [abstract]. Ann Rheum Dis. 2021;80:538. Accessed 20 Feb 2023.","DOI":"10.1136\/annrheumdis-2021-eular.1298"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00609-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00609-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00609-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T16:42:50Z","timestamp":1700152970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00609-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["609"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00609-2","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,31]]},"assertion":[{"value":"18 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anisha B Dua reports consulting\/advisory board for AbbVie, Novartis and ChemoCentryx; and is a board member of Vasculitis foundation and Chicago Rheumatism Society (not paid). Kerri Ford and Stefano Fiore are employees of Sanofi and may hold stock and\/or stock options in the company. Dimitrios A Pappas reports consulting for Sanofi, AbbVie; Gtech Roche Hellas, and Novartis; is an employee of CorEvitas LLC; has equity interest in CorEvitas, LLC; and is a member of the Board of Directors, Corrona Research Foundation. Taylor Blachley is an employee of CorEvitas, LLC and has no disclosures. Carla Roberts-Toler was an employee of CorEvitas, LLC at the time this study was conducted; currently, she is an employee of Harvard T. H. Chan School of Public Health and has no disclosures. Jud C Janak was an employee of CorEvitas, LLC at the time this study was conducted; and has no disclosures. Kelechi Emeanuru was an employee of CorEvitas, LLC at the time this study was conducted; currently, she is an employee of Evidera and has no disclosures. Joel M Kremer is a consultant for CorEvitas, LLC. Alan Kivitz has received study funding, medical writing support, and article processing charges from Amgen; has received consulting fees from Pfizer, Janssen, Boehringer Ingelheim, AbbVie, Flexion, Gilead, Grunenthal, Orion, Regeneron, Sun Pharma Advance Research, and ECOR1; has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Merck & Co, Eli Lilly, Novartis, Pfizer, Flexion, AbbVie, Amgen, Genentech, Regeneron, UCB, Horizon, and GSK; has participated in a data safety monitoring board for AbbVie and Amgen; has been part of a board or advisory board for AbbVie, Bendcare, Boehringer Ingelheim, ChemoCentryx, Flexion, Gilead, Grunenthal, Horizon, Eli Lilly, Janssen, Pfizer, Regeneron, UCB, and Novartis; and has stock or stock options in Pfizer, GSK, Gilead, Novartis, and Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and all participating investigators obtained full ethics or institutional review board (IRB) approval for conducting research in patients. The Sponsor approval and continuing review were obtained through a central IRB, New England Independent Review Board (NEIRB No. 120160610). For academic investigative sites that did not receive a waiver to use the central IRB, approval was obtained from the respective governing IRBs, and documentation of approval was submitted to the Sponsor prior to initiating any study procedures. All registry patients were required to provide written informed consent prior to participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}